A psychometric analysis of outcome measures in peripheral spondyloarthritis. - Wikidata - wikimedia - TriplyDB

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

http://www.wikidata.org/entity/Q37085650

about

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.

P2860

Q52807790-852CBBFD-5AB1-408B-9513-F798480AF3E4 Q53781450-21E079A8-41FD-42FC-ABF2-690D82718523

P2860

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

http://www.wikidata.org/entity/Q37085650

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@en

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@nl

type

label

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@en

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@nl

prefLabel

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@en

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@nl

P1433

Q37085650-1E8808FC-D3FB-46EF-8347-E4EF314B7252

P1476

Q37085650-4F4E55AE-CA53-4273-841F-DF0726FDD19B

P2093

Q37085650-3D5FA556-E53E-4839-9D98-C4C741B71F0A

Q37085650-5430BDBD-CEE6-4907-81D3-6E4E774F003D

Q37085650-6726BA49-54A1-4C85-82D6-59B5A1404EC6

Q37085650-CD0830D6-5907-446B-A6C5-5D12A40BFAF2

Q37085650-E72B2C68-E8CF-4939-BAB1-BE788A0FC06F

Q37085650-F0421FBC-8EB7-41A9-AC33-80F0B3969F60

P2860

Q37085650-015F9135-C6CA-4851-B61C-463E41AC70FF

Q37085650-044A5D69-2779-4D79-8777-5DBF2BC9AE06

Q37085650-1720C07C-A5B1-4329-ADE1-4F70C48D91F0

Q37085650-3A054611-B22B-4B40-9F5F-7D57098B72F7

Q37085650-60ED9244-397D-44CA-A29F-AC9539F18DCD

Q37085650-6266B504-AAEA-4D7D-90B7-559C59D37C6E

Q37085650-65DB4622-72A9-4C1C-954E-298CE396744E

Q37085650-6B07DF4F-600C-4B2D-BDA8-434008DC5FD2

Q37085650-8DDEBF6E-5F8A-426D-81E6-DAB43D6D9239

Q37085650-97AABC10-08B8-49A2-9EBE-7CB887E26A48

P304

Q37085650-E668CA0E-CB7D-43E7-947E-14DEA7E5FB71

P31

Q37085650-5F170761-CF13-4AC1-8F28-40920DC2B6AC

P356

Q37085650-FEBF0B14-A782-46A6-9E0A-E8E6588BF812

P407

Q37085650-D535A44D-9D35-425F-AB5F-9A4FE31AF13C

P433

Q37085650-D70DA9F9-F606-4A81-AD6C-47CF051F42D5

P478

Q37085650-B64E5817-3D0D-40EF-9BAB-1390B5CE11DB

P50

Q37085650-974D5AFB-CAC7-44EB-AD9D-CF51B423FFBD

Q37085650-FE787799-7642-4AD1-8518-5E27C8D2B7E4

P577

Q37085650-2AB75AD9-E402-482E-B04B-6B770FE53DBB

P5875

Q37085650-27C2D4BA-DC5B-4C9A-9744-21B24A314235

P698

Q37085650-0F855CE2-F11B-41F1-AAF3-BAA2A428C52D

P932

Q37085650-4E3A53EA-F69D-48D0-A42B-8E74764DCB30

P356

ANNRHEUMDIS-2014-207235

P1433

Annals of the Rheumatic Diseases

P1476

A psychometric analysis of outcome measures in peripheral spondyloarthritis.

@en

P2093

Aileen L Pangan

http://www.w3.org/2001/XMLSchema#string

Dominique L Baeten

http://www.w3.org/2001/XMLSchema#string

In-Ho Song

http://www.w3.org/2001/XMLSchema#string

Jacqueline E Paramarta

http://www.w3.org/2001/XMLSchema#string

Maureen C Turina

http://www.w3.org/2001/XMLSchema#string

Philip Mease

http://www.w3.org/2001/XMLSchema#string

P2860

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Spondyloarthritis.

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

P304

1302-1307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2014-207235

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Robert Landewé

P577

2015-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284305825

http://www.w3.org/2001/XMLSchema#string

P698

26245756

http://www.w3.org/2001/XMLSchema#string

P932

4941177

http://www.w3.org/2001/XMLSchema#string